IDEXX Laboratories Inc (IDXX)

Return on equity (ROE)

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income (ttm) US$ in thousands 845,042 822,728 791,435 699,178 679,089 669,653 663,950 734,553 744,845 756,864 727,848 674,206 581,776 497,482 460,100 436,866 427,720 422,862 407,276 390,261
Total stockholders’ equity US$ in thousands 1,484,530 1,297,410 1,093,860 841,101 608,737 475,999 457,008 639,798 689,992 754,754 747,460 702,696 632,088 440,576 272,963 107,674 177,473 202,418 171,246 51,562
ROE 56.92% 63.41% 72.35% 83.13% 111.56% 140.68% 145.28% 114.81% 107.95% 100.28% 97.38% 95.95% 92.04% 112.92% 168.56% 405.73% 241.01% 208.91% 237.83% 756.88%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $845,042K ÷ $1,484,530K
= 56.92%

Idexx Laboratories, Inc. has exhibited a fluctuating trend in its return on equity (ROE) over the past eight quarters. The ROE decreased significantly from 145.28% in Q2 2022 to 56.92% in Q4 2023. Despite this decline, the company's ROE remained relatively high compared to the industry average during most of the periods analyzed. It peaked at 140.68% in Q3 2022 and saw a gradual decline until Q4 2023.

The high ROE values indicate that Idexx Laboratories has been effective in generating profit from its shareholders' equity. However, the decreasing trend in recent quarters may suggest a decline in profitability efficiency or a potential change in the capital structure of the company. Further analysis of the company's financial performance and management strategies is recommended to better understand the factors influencing the fluctuation in ROE over time.


Peer comparison

Dec 31, 2023